---
title: Hippo Health Platform gains official market approval in Finland
description: HippocrAItes’ Hippo Health Platform has been approved under category A1 of the Astori Register maintained by Valvira.
---

[Hippocraites - News](https://hippocraites.fi/news)

# [Hippo Health Platform gains official market approval in Finland](https://hippocraites.fi/news/hippo-health-platform-gains-official-market-approval-in-finland)

 Written by [HippocrAItes](https://hippocraites.fi/news/author/hippocraites) | Jun 23, 2025, 2:41:45 PM

## Hippo Health Platform has received official approval for use in the Finnish healthcare sector from [Valvira](https://valvira.fi/en/frontpage), the National Supervisory Authority for Welfare and Health in Finland. 

This approval confirms that the platform meets Finland’s national requirements for data security, interoperability, and regulatory compliance in the health and social care system.

 

## A1 classification validates that Hippo Health Platform: 

- Is approved for clinical use in Finnish social and healthcare service organizations
- Complies with Finnish and EU data protection and interoperability standards
- Is compatible with national services, including the [Kanta](https://www.kanta.fi/en/) system
- Is validated for primary care

 The registration enables HippocrAItes to operate within the healthcare sector and collaborate with trusted partners, such as [Amazon Web Services](https://aws.amazon.com/), in developing secure and scalable digital health solutions. 

“Valvira’s approval enables the clinical use of the [Hippo Health Platform](https://hippocraites.fi/news/what-is-hippo-health-platform?hsLang=en) in Finland. This marks the first step in the platform’s commercialization. We have now launched pilot projects aimed at validating the platform’s impact on healthcare professionals’ workflows. We will share the results of the pilot in October 2025,” confirms Juuso Haavisto, CEO of HippocrAItes.

## Categories A1-A3 in Astori-register

Hippo Health Platform was approved for Category A1 classification.

 

For more information and interview requests:

Juuso Haavisto  
CEO  
[juuso.haavisto@hippocraites.fi](mailto:juuso.haavisto@hippocraites.fi)  
tel. +358 50 351 1925  
HippocrAItes

Join us at our Future Health event on October 2, 2025, in Meilahti, where we’ll present the pilot results!

 

[View full post](https://hippocraites.fi/news/hippo-health-platform-gains-official-market-approval-in-finland)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "HippocrAItes"
  },
  "dateModified" : "2025-09-24T12:19:34.842Z",
  "datePublished" : "2025-06-23T14:41:45Z",
  "headline" : "Hippo Health Platform gains official market approval in Finland",
  "image" : {
    "@type" : "ImageObject",
    "height" : 600,
    "url" : "https://144397312.fs1.hubspotusercontent-eu1.net/hubfs/144397312/Valvira%20A1_HippocrAItes_hero.png",
    "width" : 1200
  },
  "mainEntityOfPage" : "https://hippocraites.fi/news/hippo-health-platform-gains-official-market-approval-in-finland",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "News"
  }
}
```